Bychkov M L, Shulepko M A, Shlepova O V, Lyukmanova E N, Kirpichnikov M P
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997, Moscow, Russia.
Moscow Institute of Physics and Technology (National Research University), 141701, Dolgoprudnyi, Moscow oblast, Russia.
Dokl Biochem Biophys. 2019 Nov;489(1):392-395. doi: 10.1134/S1607672919060103. Epub 2020 Mar 4.
In the present study we showed that the recombinant analogue of the SLURP-1 protein effectively inhibits the growth of a 3D model of tumors-multicellular spheroids reconstructed from human epidermoid carcinoma A431 cells and human lung adenocarcinoma A549 cells. The combined application of rSLURP-1 with gefitinib (inhibitor of epidermal growth factor receptor (EGFR)) leads to the synergistic antiproliferative effect on spheroids from A431 cells. The results obtained suggest the possibility for design of first-in-class anticancer drugs based on recombinant SLURP-1.
在本研究中，我们表明SLURP-1蛋白的重组类似物可有效抑制由人表皮样癌A431细胞和人肺腺癌A549细胞重建的肿瘤多细胞球体三维模型的生长。rSLURP-1与吉非替尼（表皮生长因子受体（EGFR）抑制剂）联合应用对A431细胞来源的球体产生协同抗增殖作用。所得结果提示了基于重组SLURP-1设计一类新型抗癌药物的可能性。
